343 related articles for article (PubMed ID: 36791151)
21. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.
Yang C; Yu T; Li Q; Xie F; Lin Q
Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449
[TBL] [Abstract][Full Text] [Related]
22. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
23. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas.
Cai Z; Zhang J; Liu Z; Su J; Xu J; Li Z; Meng H; Zhang H; Huang M; Zhao D; Duan C; He X
Ann Transl Med; 2021 Aug; 9(15):1241. PubMed ID: 34532378
[TBL] [Abstract][Full Text] [Related]
24. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
[No Abstract] [Full Text] [Related]
26. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
27. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
28. Prognostic values of m6A RNA methylation regulators in differentiated Thyroid Carcinoma.
Xu N; Chen J; He G; Gao L; Zhang D
J Cancer; 2020; 11(17):5187-5197. PubMed ID: 32742465
[TBL] [Abstract][Full Text] [Related]
29. Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma.
Fang J; Hu M; Sun Y; Zhou S; Li H
DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33085515
[TBL] [Abstract][Full Text] [Related]
30. Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation.
Quan Y; Zhang X; Wang M; Ping H
Front Oncol; 2022; 12():981226. PubMed ID: 36237332
[TBL] [Abstract][Full Text] [Related]
31. Identification of m6A-related lncRNAs for thyroid cancer recurrence.
Wang X; Su D; Wei Y; Liu S; Gao S; Tian H; Wei W
Gland Surg; 2023 Jan; 12(1):39-53. PubMed ID: 36761480
[TBL] [Abstract][Full Text] [Related]
32. N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS).
Zhou S; Hua R; Quan S
J Ovarian Res; 2023 Apr; 16(1):73. PubMed ID: 37046273
[TBL] [Abstract][Full Text] [Related]
33. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
34. m6A modification patterns are associated with copy number burden and tumor immune landscape in thyroid cancer.
Cai L; Liu T; Hua H; Jiang X; Qian L
BMC Endocr Disord; 2023 Dec; 23(1):271. PubMed ID: 38057752
[TBL] [Abstract][Full Text] [Related]
35. Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma.
Zhang L; Zhang Q; Huang Z; Zhu M; Wang T; Zhu W; Wang X; Zhou X
Biomed Res Int; 2022; 2022():2053719. PubMed ID: 36193316
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
37. Construction and validation of an m6A RNA methylation regulator prognostic model for early-stage clear cell renal cell carcinoma.
Wang Z; Zhang M; Seery S; Zheng G; Wang W; Zhao Y; Wang X; Zhang Y
Oncol Lett; 2022 Aug; 24(2):250. PubMed ID: 35761938
[TBL] [Abstract][Full Text] [Related]
38. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
39. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
